Prof. Fazlul
H. Sarkar
Wayne State
University, USA
E-mail: fsarkar@med.wayne.edu
Qualifications
1978 PhD Biochemistry, Banaras Hindu, University, India
1974 Graduate:
M.Sc., Biochemistry, Aligarh Muslim, University, India (First Class)
1971 Baccalaureate:
B.Sc., Physics, Chemistry, Math, Calcutta University, India (Distinction)
Publications
(Selected)
-
S. Ali, A.
Ahmad, S. Banerjee, S. Padhye, K. Dominiak, J. M. Schaffert, Z. Wang, P. A.
Philip, and F. H. Sarkar. Gemcitabine sensitivity can be induced in
pancreatic cancer cells through modulation of miR-200 and miR-21 expression by
curcumin or its analogue CDF. Cancer Res. 70 (9):3606-3617, 2010.
-
A. S. Azmi, P.
A. Philip, A. Aboukameel, Z. Wang, S. Banerjee, S. F. Zafar, A. S. Goustin, K.
Almhanna, D. Yang, F. H. Sarkar, and R. M. Mohammad. Reactivation of p53
by novel MDM2 inhibitors: implications for pancreatic cancer therapy. Curr.Cancer
Drug Targets. 10 (3):319-331, 2010.
-
S. Ali, S.
Banerjee, J. M. Schaffert, B. F. El-Rayes, P. A. Philip, and F. H. Sarkar.
Concurrent inhibition of NFkappaB, cyclooxygenase-2, and epidermal growth
factor receptor leads to greater anti-tumor activity in pancreatic cancer. J
Cell Biochem. 110 (1):171-181, 2010.
-
F. H. Sarkar.
(Part I) Recent trends in anti-cancer drug discovery. Mini.Rev.Med Chem. 10
(5):357-358, 2010.
-
S. Padhye, D.
Chavan, S. Pandey, J. Deshpande, K. V. Swamy, and F. H. Sarkar.
Perspectives on chemopreventive and therapeutic potential of curcumin analogs
in medicinal chemistry. Mini.Rev.Med Chem. 10 (5):372-387, 2010.
-
A. Ahmad, Z.
Wang, R. Ali, M. Y. Maitah, D. Kong, S. Banerjee, S. Padhye, and F. H.
Sarkar. Apoptosis-inducing effect of garcinol is mediated by NF-kappaB
signaling in breast cancer cells. J Cell Biochem. 109 (6):1134-1141,
2010.
-
Z. Wang, A.
Ahmad, Y. Li, S. Banerjee, D. Kong, and F. H. Sarkar. Forkhead box M1
transcription factor: a novel target for cancer therapy. Cancer Treat.Rev. 36
(2):151-156, 2010.
-
A. S. Azmi, A.
Aboukameel, S. Banerjee, Z. Wang, M. Mohammad, J. Wu, S. Wang, D. Yang, P. A.
Philip, F. H. Sarkar, and R. M. Mohammad. MDM2 inhibitor MI-319 in
combination with cisplatin is an effective treatment for pancreatic cancer
independent of p53 function. Eur.J Cancer 46 (6):1122-1131, 2010.
-
S. Banerjee,
M. Choi, A. Aboukameel, Z. Wang, M. Mohammad, J. Chen, D. Yang, F. H.
Sarkar, and R. M. Mohammad. Preclinical studies of apogossypolone, a novel pan
inhibitor of bcl-2 and mcl-1, synergistically potentiates cytotoxic effect of
gemcitabine in pancreatic cancer cells. Pancreas 39 (3):323-331,
2010.
-
Z. Wang, Y.
Li, and F. H. Sarkar. Signaling mechanism(s) of reactive oxygen species in
Epithelial-Mesenchymal Transition reminiscent of cancer stem cells in tumor
progression. Curr.Stem Cell Res.Ther. 5 (1):74-80, 2010.
-
Z. Wang, Y.
Li, S. Banerjee, D. Kong, A. Ahmad, V. Nogueira, N. Hay, and F. H. Sarkar.
Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth,
migration and invasion, and induces apoptosis via inactivation of Akt, mTOR,
and NF-kappaB signaling pathways. J Cell Biochem. 109 (4):726-736,
2010.
-
Y. Li, T. G.
Vandenboom, Z. Wang, D. Kong, S. Ali, P. A. Philip, and F. H. Sarkar.
miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res. 70
(4):1486-1495, 2010.
-
S. Adsule, S.
Banerjee, F. Ahmed, S. Padhye, and F. H. Sarkar. Hybrid anticancer agents:
isothiocyanateprogesterone conjugates as chemotherapeutic agents and insights
into their cytotoxicities. Bioorg.Med Chem.Lett. 20 (3):1247-1251,
2010.
-
B. F.
El-Rayes, P. A. Philip, F. H. Sarkar, A. F. Shields, A. M. Ferris, K.
Hess, A. O. Kaseb, M. M. Javle, G. R. Varadhachary, R. A. Wolff, and J. L.
Abbruzzese. A phase II study of isoflavones, erlotinib, and gemcitabine in
advanced pancreatic cancer. Invest New Drugs, 2010.
-
I. U. Ahmad,
J. D. Forman, F. H. Sarkar, G. G. Hillman, E. Heath, U. Vaishampayan, M.
L. Cher, F. Andic, P. J. Rossi, and O. Kucuk. Soy isoflavones in conjunction
with radiation therapy in patients with prostate cancer. Nutr.Cancer 62
(7):996-1000, 2010.
-
S. Banerjee,
S. Padhye, A. Azmi, Z. Wang, P. A. Philip, O. Kucuk, F. H. Sarkar, and R.
M. Mohammad. Review on molecular and therapeutic potential of thymoquinone in
cancer. Nutr.Cancer 62 (7):938-946, 2010.
-
B. Bao, Z.
Wang, Y. Li, D. Kong, S. Ali, S. Banerjee, A. Ahmad, and F. H. Sarkar. The
complexities of obesity and diabetes with the development and progression of
pancreatic cancer. Biochim.Biophys.Acta 1815 (2):135-146, 2011.
-
S. Liao, J.
Xia, Z. Chen, S. Zhang, A. Ahmad, L. Miele, F. H. Sarkar, and Z. Wang.
Inhibitory effect of curcumin on oral carcinoma CAL-27 cells via suppression of
Notch-1 and NF-kappaB signaling pathways. J Cell Biochem. 112
(4):1055-1065, 2011.
-
S. S. Kanwar,
Y. Yu, J. Nautiyal, B. B. Patel, S. Padhye, F. H. Sarkar, and A. P.
Majumdar. Difluorinated-Curcumin (CDF): A Novel Curcumin Analog is a Potent
Inhibitor of Colon Cancer Stem-Like Cells. Pharm.Res. 28 (4):827-838,
2011.
-
B. Bao, A. S.
Prasad, F. W. Beck, G. W. Bao, T. Singh, S. Ali, and F. H. Sarkar.
Intracellular free zinc up-regulates IFN-gamma and T-bet essential for Th(1)
differentiation in Con-A stimulated HUT-78 cells. Biochem.Biophys.Res.Commun.,
2011.
-
S.
Patitungkho, S. Adsule, P. Dandawate, S. Padhye, A. Ahmad, and F. H.
Sarkar. Synthesis, characterization and anti-tumor activity of
moxifloxacin-Copper complexes against breast cancer cell lines. Bioorg.Med
Chem.Lett. 21(6):1802-1806, 2011.
-
A. Ahmad, A.
Aboukameel, D. Kong, Z. Wang, S. Sethi, W. Chen, F. H. Sarkar, and A. Raz.
Phosphoglucose Isomerase/Autocrine Motility Factor mediates
epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. Cancer
Res., 2011.
-
A. S. Azmi, F.
W. Beck, F. H. Sarkar, and R. M. Mohammad. Network Perspectives on HDM2
InhibitorChemotherapy Combinations. Curr.Pharm.Des, 2011.27
-
B. Bao, S.
Ali, D. Kong, S. H. Sarkar, Z. Wang, S. Banerjee, A. Aboukameel, S. Padhye, P.
A. Philip, and F. H. Sarkar. Anti-Tumor Activity of a Novel Compound-CDF
Is Mediated by Regulating miR-21, miR-200, and PTEN in Pancreatic Cancer. PLoS.One. 6
(3):e17850, 2011.
-
A. S. Azmi, Z.
Wang, P. A. Philip, R. M. Mohammad, and F. H. Sarkar. Emerging Bcl-2
inhibitors for the treatment of cancer. Expert.Opin.Emerg.Drugs 16
(1):59-70, 2011.
-
S. Banerjee,
D. Kong, A. S. Azmi, Z. Wang, A. Ahmad, S. Sethi, and F. H. Sarkar.
Restoring sensitivity to oxaliplatin by a novel approach in
gemcitabine-resistant pancreatic cancer cells in vitro and in vivo. Int.J
Cancer 128 (5):1240-1250, 2011.
-
J. Nautiyal,
S. Banerjee, S. S. Kanwar, Y. Yu, B. B. Patel, F. H. Sarkar, and A. P. Majumdar.
Curcumin enhances dasatinib-induced inhibition of growth and transformation of
colon cancer cells. Int.J Cancer 128 (4):951-961, 2011.
-
V.
Singh-Gupta, M. C. Joiner, L. Runyan, C. K. Yunker, F. H. Sarkar, S.
Miller, S. M. Gadgeel, A. A. Konski, and G. G. Hillman. Soy Isoflavones Augment
Radiation Effect by Inhibiting APE1/Ref-1 DNA Repair Activity in Non-small Cell
Lung Cancer. J Thorac.Oncol., 2011.
-
A. S. Jaiswal,
S. Banerjee, R. Aneja, F. H. Sarkar, D. A. Ostrov, and S. Narayan. DNA
polymerase beta as a novel target for chemotherapeutic intervention of
colorectal cancer. PLoS.One. 6 (2):e16691, 2011.
-
A. Ahmad, Z.
Wang, D. Kong, R. Ali, S. Ali, S. Banerjee, and F. H. Sarkar.
Platelet-derived growth factor-D contributes to aggressiveness of breast cancer
cells by up-regulating Notch and NF-kappaB signaling pathways. Breast
-
Cancer
Res.Treat. 126 (1):15-25, 2011.
-
M. Y. Maitah,
S. Ali, A. Ahmad, S. Gadgeel, and F. H. Sarkar. Up-regulation of sonic
hedgehog contributes to TGFbeta1-induced epithelial to mesenchymal transition
in NSCLC cells. PLoS.One. 6 (1):e16068, 2011.
-
A. S. Azmi, P.
A. Philip, F. W. Beck, Z. Wang, S. Banerjee, S. Wang, D. Yang, F. H.
Sarkar, and R. M. Mohammad. MI-219-zinc combination: a new paradigm in MDM2
inhibitor-based therapy. Oncogene 30 (1):117-126, 2011.
-
Z. Wang, Y.
Li, A. Ahmad, S. Banerjee, A. S. Azmi, D. Kong, C. Wojewoda, L. Miele, and F.
H. Sarkar. Downregulation of Notch-1 is associated with Akt and FoxM1 in
inducing cell growth inhibition and apoptosis in prostate cancer cells. J
Cell Biochem. 112 (1):78-88, 2011.
-
Z. Wang, Y.
Li, A. Ahmad, S. Banerjee, A. S. Azmi, D. Kong, and F. H. Sarkar.
Pancreatic cancer: understanding and overcoming
chemoresistance.Nat.Rev.Gastroenterol.Hepatol. 8 (1):27-33, 2011.
-
D. Dou, A.
Ahmad, H. Yang, and F. H. Sarkar. Tumor cell growth inhibition is
correlated with levels of capsaicin present in hot peppers. Nutr.Cancer 63
(2):272-281, 2011.
-
Bao B, Wang Z,
Ali S, Kong D, Li Y, Ahmad A, Banerjee S, Azmi AS, Miele L, Sarkar FH.
Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem
cell phenotype in pancreatic cancer cells. Cancer Lett. 2011;307(1):26-36.
PMC3104092.
-
El-Rayes BF,
Philip PA, Sarkar FH, Shields AF, Ferris AM, Hess K, Kaseb AO, Javle MM,
Varadhachary GR, Wolff RA, Abbruzzese JL. A phase II study of isoflavones,
erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs.
2011;29(4):694-9. PMID: 20107864.
-
Ahmad A, Wang
Z, Wojewoda C, Ali R, Kong D, Maitah MY, Banerjee S, Bao B, Padhye S, Sarkar
FH. Garcinolinduced apoptosis in prostate and pancreatic cancer cells is
mediated by NF- KappaB signaling. Front Biosci (Elite Ed). 2011 Jun
1;3:1483-92. PMID: 21622152.
-
Azmi AS,
Banerjee S, Ali S, Wang Z, Bao B, Beck FW, Maitah M, Choi M, Shields TF, Philip
PA, Sarkar FH, Mohammad RM. Network Modeling of MDM2 Inhibitor-Oxaliplatin
Combination Reveals Biological Synergy in wtp53 solid tumors. Oncotarget. 2011
May 16. PMID: 21623005.
-
Hillman GG,
Singh-Gupta V, Al-Bashir AK, Yunker CK, Joiner MC, Sarkar FH, Abrams J,
Haacke EM. Monitoring sunitinib-induced vascular effects to optimize
radiotherapy combined with soy isoflavones in murine xenograft tumor. Transl
Oncol. 2011;4(2):110-21. PMC3069654.
-
Kong D, Li Y,
Wang Z, Sarkar FH. Cancer Stem Cells and Epithelial-to-Mesenchymal
Transition (EMT)-Phenotypic Cells: Are They Cousins or Twins? Cancers (Basel).
2011;3(1):716-729. PMC3106306.
-
Azmi AS, Beck
FW, Sarkar FH, Mohammad RM. Network perspectives on HDM2 inhibitor
chemotherapy combinations. Curr Pharm Des. 2011;17(6):640-52. PMID: 21391913.